Refractory thrombocytopenia due to anti-PLA1 antibodies following autologous peripheral blood stem cell transplantation: case report and review of literature.
A 43-year-old woman developed life-threatening refractory thrombocytopenia following autologous peripheral blood stem cell transplantation for metastatic breast carcinoma. Anti-PLA1 antibodies were demonstrated in the patient's plasma. Treatment with intravenous immunoglobulin and transfusion of PLA1-negative blood products restored platelet responsiveness. PLA1 allo-antibodies should be considered as a possible cause of severe refractory thrombocytopenia in marrow transplant patients. It is important to make this diagnosis as the mainstay of treatment is the avoidance of blood products from PLA1-positive donors (98% of the population).
Roy
V
V
Department of Medicine, University of Minnesota Medical School, Minneapolis 55455, USA.
Verfaillie
C M
CM
D000328:Adult; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D013921:Thrombocytopenia / Q000209:etiology*; D014182:Transplantation, Autologous
D017152:Antibodies, Antiphospholipid